Terms: = Lymphoma AND MLLT3, AF9, 4300, ENSG00000171843, P42568, YEATS3, AF-9 AND Treatment
27 results:
1. Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication.
Liu Y; Klein J; Bajpai R; Dong L; Tran Q; Kolekar P; Smith JL; Ries RE; Huang BJ; Wang YC; Alonzo TA; Tian L; Mulder HL; Shaw TI; Ma J; Walsh MP; Song G; Westover T; Autry RJ; Gout AM; Wheeler DA; Wan S; Wu G; Yang JJ; Evans WE; Loh M; Easton J; Zhang J; Klco JM; Meshinchi S; Brown PA; Pruett-Miller SM; Ma X
Nat Commun; 2023 Apr; 14(1):1739. PubMed ID: 37019972
[TBL] [Abstract] [Full Text] [Related]
2. An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
Jurutka PW; di Martino O; Reshi S; Mallick S; Sausedo MA; Moen GA; Lee IJ; Ivan DJ; Krall TD; Peoples SJ; Perez A; Tromba L; Le A; Khadka I; Petros R; Savage BM; Salama E; Salama J; Ziller JW; Noh Y; Lee MY; Liu W; Welch JS; Marshall PA; Wagner CE
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555852
[TBL] [Abstract] [Full Text] [Related]
3. Lineage switch in a pediatric patient with KMT2A-mllt3 from acute megakaryoblastic leukemia to T cell acute lymphoblastic leukemia at the fourth relapse after allo-HSCT: with literature review.
Gao L; Lu J; Li J; Hu Y; Lu Y; Du W; Hu S
Int J Hematol; 2023 May; 117(5):781-785. PubMed ID: 36472792
[TBL] [Abstract] [Full Text] [Related]
4. Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements.
Wen J; Zhou M; Shen Y; Long Y; Guo Y; Song L; Xiao J
BMC Cancer; 2022 Aug; 22(1):859. PubMed ID: 35933338
[TBL] [Abstract] [Full Text] [Related]
5. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).
Jurutka PW; di Martino O; Reshi S; Mallick S; Sabir ZL; Staniszewski LJP; Warda A; Maiorella EL; Minasian A; Davidson J; Ibrahim SJ; Raban S; Haddad D; Khamisi M; Suban SL; Dawson BJ; Candia R; Ziller JW; Lee MY; Liu C; Liu W; Marshall PA; Welch JS; Wagner CE
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830251
[TBL] [Abstract] [Full Text] [Related]
6. Mature B cell acute lymphoblastic leukaemia with KMT2A-mllt3 transcripts in children: three case reports and literature reviews.
Cui Y; Zhou M; Zou P; Liao X; Xiao J
Orphanet J Rare Dis; 2021 Jul; 16(1):331. PubMed ID: 34330316
[TBL] [Abstract] [Full Text] [Related]
7. Therapy-induced Deletion in 11q23 Leading to Fusion of
Panagopoulos I; Andersen K; Eilert-Olsen M; Zeller B; Munthe-Kaas MC; Buechner J; Osnes LTN; Micci F; Heim S
Cancer Genomics Proteomics; 2021; 18(1):67-81. PubMed ID: 33419897
[TBL] [Abstract] [Full Text] [Related]
8. Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.
Matsuo H; Yoshida K; Nakatani K; Harata Y; Higashitani M; Ito Y; Kamikubo Y; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Miyano S; Meggendorfer M; Haferlach C; Ogawa S; Adachi S
Blood Adv; 2020 Oct; 4(19):4623-4631. PubMed ID: 32991719
[TBL] [Abstract] [Full Text] [Related]
9. MLL-Rearranged Acute Lymphoblastic Leukemia.
El Chaer F; Keng M; Ballen KK
Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
[TBL] [Abstract] [Full Text] [Related]
10. EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.
Saito Y; Sawa D; Kinoshita M; Yamada A; Kamimura S; Suekane A; Ogoh H; Matsuo H; Adachi S; Taga T; Tomizawa D; Osato M; Soga T; Morishita K; Moritake H
Haematologica; 2020 Aug; 105(8):2118-2129. PubMed ID: 31649131
[TBL] [Abstract] [Full Text] [Related]
11. Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.
Assaf N; El-Cheikh J; Bazarbachi A; Salem Z; Farra C; Chakhachiro Z; Nassif S; Zaatari G; Mahfouz R
Mol Biol Rep; 2019 Apr; 46(2):2003-2011. PubMed ID: 30701458
[TBL] [Abstract] [Full Text] [Related]
12. Recurrent
Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
[TBL] [Abstract] [Full Text] [Related]
13. CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion.
Jin CH; Li Y; Xia J; Li Y; Chen M; Hu Z; Mapara MY; Li W; Yang YG
Am J Hematol; 2018 Jun; 93(6):786-793. PubMed ID: 29603337
[TBL] [Abstract] [Full Text] [Related]
14. Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia.
Matsuo H; Iijima-Yamashita Y; Yamada M; Deguchi T; Kiyokawa N; Shimada A; Tawa A; Tomizawa D; Taga T; Kinoshita A; Adachi S; Horibe K
Pediatr Int; 2018 Jan; 60(1):41-46. PubMed ID: 29067751
[TBL] [Abstract] [Full Text] [Related]
15. Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-af9 treated with chidamide-based chemotherapy.
Lun Y; Yang JJ; Wu Y
J Clin Pharm Ther; 2017 Dec; 42(6):786-789. PubMed ID: 28646565
[TBL] [Abstract] [Full Text] [Related]
16. [Biological microchip for establishing the structure of fusion transcripts involving MLL in children with acute leukemia].
Nasedkina TV; Ikonnikova AY; Tsaur GA; Karateeva AV; Ammour YI; Avdonina MA; Karachunskii AI; Zasedatelev AS
Mol Biol (Mosk); 2016; 50(6):968-977. PubMed ID: 28064313
[TBL] [Abstract] [Full Text] [Related]
17. Generation of a MLL-af9-specific stem cell model of acute monocytic leukemia.
Chiew MY; Boo NY; Voon K; Cheong SK; Leong PP
Leuk Lymphoma; 2017 Jan; 58(1):162-170. PubMed ID: 27185517
[TBL] [Abstract] [Full Text] [Related]
18. MLL leukemia and future treatment strategies.
Marschalek R
Arch Pharm (Weinheim); 2015 Apr; 348(4):221-8. PubMed ID: 25740345
[TBL] [Abstract] [Full Text] [Related]
19. Multiple clonal MLL fusions in a patient receiving CHOP-based chemotherapy.
Shih SJ; Fass J; Buffalo V; Lin D; Singh SP; Diaz MO; Vaughan AT
Br J Haematol; 2012 Oct; 159(1):50-7. PubMed ID: 22845170
[TBL] [Abstract] [Full Text] [Related]
20. CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases.
Xue SL; Wu DP; Sun AN; Tang XW
Am J Hematol; 2008 Feb; 83(2):167-70. PubMed ID: 17874449
[TBL] [Abstract] [Full Text] [Related]
[Next]